EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

Nick Pavlakis iD, Kohei Shitara iD, Katrin Sjoquist iD, Andrew Martin, Anthony Jaworski, Niall Tebbutt iD, Yung-Jue Bang iD, Thierry Alcindor iD, Chris O'Callaghan, Andrew Strickland, Sun Young Rha iD, Keun-Wook Lee iD und 9 weitere

Journal of Clinical Oncology · 2025-02 · 43 (4) · 453-463

DOI: 10.1200/jco.24.00055 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-02. Verfasst von Nick Pavlakis und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Pyridines, Phenylurea Compounds, Stomach Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Treatment options for refractory advanced gastric and esophagogastric junction cancer (AGOC) are limited. Regorafenib, an oral multikinase inhibitor, prolonged progression-free survival (PFS) versus placebo in the INTEGRATE I phase II trial. INTEGRATE IIa was designed to examine whether regorafenib improved overall survival (OS). METHODS A double-blind placebo-controlled phase III trial compared regorafenib and best supportive care (BSC) versus placebo and BSC for participants with confirmed evaluable metastatic/advanced AGOC who failed ≥two prior therapies on a 2:1 random assignment, stratified by tumor location, geographic region (Asia v rest of world), and prior vascular endothelial growth factor inhibitors. The primary end point was OS. Treatment efficacy on OS was first tested in the pooled INTEGRATE I + INTEGRATE IIa cohort and, if significant, then in the INTEGRATE IIa cohort. Secondary end points were PFS, objective response rate, safety, and quality of life (QoL). RESULTS INTEGRATE IIa enrolled 251 participants: 157 from Asia and 94 from rest of world and 169 received regorafenib and 82 received placebo. No significant heterogeneity was observed between INTEGRATE I and INTEGRATE IIa studies on OS. Pooled OS analysis hazard ratio (HR) was 0.70 (95% CI, 0.56 to 0.87; P = .001; 361 events). INTEGRATE IIa alone OS HR was 0.68 (95% CI, 0.52 to 0.90; P = .006; 238 events), the median OS was 4.5 months versus 4.0 months, and 12-month survival rates were 19% and 6%, for regorafenib versus placebo, respectively. After a preplanned adjustment for multiplicity, there were no statistically significant differences across regions or other prespecified subgroups. Regorafenib improved PFS (HR, 0.53 [95% CI, 0.40 to 0.70]; P < .0001) and delayed deterioration in global QoL (HR, 0.68 [95% CI, 0.52 to 0.89]; P = .0043). The toxicity profile was consistent with that of previous reports. CONCLUSION Regorafenib improves survival compared with placebo in refractory AGOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesPhenylurea CompoundsStomach NeoplasmsAntineoplastic AgentsHumansFemaleMaleMiddle AgedDouble-Blind MethodAgedProgression-Free SurvivalAdultQuality of LifeAged, 80 and over

Substanzen

regorafenibPyridinesPhenylurea CompoundsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia.
  • University of Sydney, Sydney, NSW, Australia.
  • Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Japan.
  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Cancer Care Centre, St George Hospital, Kogarah, NSW, Australia.
  • Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, VIC, Australia.

ORCID-Profile: Nick Pavlakis, Kohei Shitara, Katrin Sjoquist, Niall Tebbutt, Yung-Jue Bang, Thierry Alcindor, Sun Young Rha, Keun-Wook Lee, Jin-Soo Kim, Li-Yuan Bai, Hiroki Hara, Do-Youn Oh, Sonia Yip, John Zalcberg, Tim Price

Zitieren

APA

Pavlakis, N., Shitara, K., Sjoquist, K., Martin, A., Jaworski, A., Tebbutt, N., Bang, Y. J., Alcindor, T., O'Callaghan, C., Strickland, A., Rha, S. Y., Lee, K. W., Kim, J. S., Bai, L. Y., Hara, H., Oh, D. Y., Yip, S., Zalcberg, J., Price, T., …, & Goldstein, D. (2025). INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. Journal of Clinical Oncology, 43(4), 453-463. https://doi.org/10.1200/jco.24.00055

Vancouver

Pavlakis N, Shitara K, Sjoquist K, Martin A, Jaworski A, Tebbutt N, et al. INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. Journal of Clinical Oncology. 2025;43(4):453-463. doi:10.1200/jco.24.00055

BibTeX
@article{Pavlakis2025,
  author = {Pavlakis, Nick and Shitara, Kohei and Sjoquist, Katrin and Martin, Andrew and Jaworski, Anthony and Tebbutt, Niall and Bang, Yung-Jue and Alcindor, Thierry and O'Callaghan, Chris and Strickland, Andrew and Rha, Sun Young and Lee, Keun-Wook and Kim, Jin-Soo and Bai, Li-Yuan and Hara, Hiroki and Oh, Do-Youn and Yip, Sonia and Zalcberg, John and Price, Tim and Simes, John and Goldstein, David},
  title = {INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {4},
  pages = {453--463},
  doi = {10.1200/jco.24.00055}
}
Kostenlos starten →